SCHEDULE 13G: Commodore Capital Discloses 7.6% Passive Stake in Solid Biosciences Inc.

Commodore Capital LP and Commodore Capital Master LP have jointly reported a passive beneficial ownership of 7.6% in Solid Biosciences Inc., totaling 5,825,000 shares of common stock.

Summary

• Commodore Capital LP, a Delaware limited partnership, and Commodore Capital Master LP, a Cayman Islands exempted limited partnership, have filed a Schedule 13G.
• The filing discloses their beneficial ownership of 5,825,000 shares of common stock in Solid Biosciences Inc.
• This ownership represents 7.6% of Solid Biosciences Inc.'s outstanding common stock, based on 76,318,810 shares reported as issued and outstanding in the Issuer's Rule 424(b)(5) Prospectus filed on February 18, 2025.
• Commodore Capital LP acts as the investment manager to Commodore Capital Master LP.
• Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital LP and exercise investment discretion over these securities.
• The shares are held with shared voting and shared dispositive power by the reporting persons.
• The acquisition of these securities was not for the purpose of changing or influencing the control of Solid Biosciences Inc.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the issuer's performance or outlook. The investment is stated as passive.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future performance or operations.

Industry Context

This filing indicates a significant passive investment by an investment firm in a biotechnology company. Such investments are common in the industry, reflecting investor interest in specific companies or sectors, but this filing does not provide broader industry trend analysis.

Stakeholder Impact

• Shareholders: The disclosure of a new significant ownership stake by an investment firm may be viewed as a vote of confidence, potentially influencing investor perception and trading activity.

Key Dates

Keywords

Solid Biosciences Inc., Commodore Capital LP, Commodore Capital Master LP, Beneficial Ownership, Schedule 13G, Common Stock, Investment Management, Passive Investment, Biotechnology